Shinsaku Nakagawa

This inventor holds 8 USPTO granted patents and 3 published patent applications and 6 EPO patents. Top assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Chugai Seiyaku Kabushiki Kaisha, Nitto-Denko Corporation. Active years: 2002-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinsaku Nakagawa. Retrieved from https://idiyas.com/inventor/shinsaku-nakagawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 12.5

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Yao-shi, Osaka, JP (2007 - 2010)
Osaka, JP (2002 - 2011)
Suita, JP (2011)
Yao, JP (2012)

Company Filing History:

4 out of 375

Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

patents

3 out of 991

Chugai Seiyaku Kabushiki Kaisha

patents

1 out of 3,953

Nitto-Denko Corporation

5. 4 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2012

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8187584 - Human tumor necrosis factor-α mutants (2012-05-29),

2. 7993636 - Tumor necrosis factor-alpha mutants (2011-08-09),

3. 7989588 - Cell permeable peptide (2011-08-02),

4. 7666403 - Mutant interferon α protein and use thereof (2010-02-23),

5. 7189824 - Tumor vessel endothelial cell-binding monoclonal antibodies (2007-03-13),

6. 7179891 - Physiologically active complex (2007-02-20),

7. 6875448 - Method of intracellular sustained-release of drug and preparations (2005-04-05),

8. 6440733 - Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel (2002-08-27),

Title: **Shinsaku Nakagawa: Innovator in Tumor Necrosis Factor Research**

Introduction

Shinsaku Nakagawa is a renowned inventor based in Osaka, Japan, known for his significant contributions to the field of biotechnology and protein engineering. With a total of 8 patents to his name, Nakagawa has focused predominantly on tumor necrosis factor (TNF) mutants, which play a vital role in the understanding and treatment of various diseases.

Latest Patents

Nakagawa's latest patents revolve around human tumor necrosis factor-alpha mutants. One of his primary inventions aims to provide a mutant protein specific to TNF-R1 or TNF-R2, which serves as an effective ingredient in TNF preparations. The patents detail the innovative replacement of specific amino acid residues within the protein, thereby enhancing its functionality and potential therapeutic applications. These breakthroughs emphasize the importance of targeting TNF pathways in the treatment of inflammatory diseases and conditions.

Career Highlights

Throughout his career, Shinsaku Nakagawa has been associated with notable organizations, including Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo. His work there has paved the way for advancements in biotechnology and has significantly impacted the medical research community.

Collaborations

In the course of his career, Nakagawa has collaborated with several esteemed professionals in the field, including Tadanori Mayumi and Yasuo Tsutsumi. These collaborations have fostered a spirit of innovation and have led to the successful development of various patented technologies.

Conclusion

Shinsaku Nakagawa's contributions to the field of tumor necrosis factor research through his innovative patents underscore his role as a key inventor in biotechnology. His work continues to inspire advancements in medical science, showcasing the vital connection between innovation and healthcare.

Profile summary based on public USPTO records.